12:00 AM
Apr 27, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SGI-1776: Phase I started

SuperGen began a dose-escalation, U.S. and U.K. Phase I trial to evaluate oral SGI-1776 in patients.

SuperGen Inc. (NASDAQ:SUPG), Dublin,...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >